Novo, Sanofi and Merck & Co all scored exits as the cancer drug developer, which had been spun off by Biox Biosciences, floated in a $101m offering.

Queen’s University Belfast’s tech transfer office has launched a fund in partnership with Sapphire Capital Partners to invest in its spinouts.

The Finaves-backed developer of brain implant technology based on research from University of Manchester has secured series A funding.

GV led the first disclosed round for the anti-viral nasal spray developer, investing $47.2m together with F-Prime Capital, Casdin Capital and Brook Byers.

Marui Group, Q’sfix and Giftee have contributed to a $13.7m first close that represents half of the fund's target for its final close.

UniCredit, Swedbank, Groupe BPCE and Íslandsbanki contributed to an $11.8m round that took the banking software provider's total funding past $55m.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Tencent helped the grocery delivery service become the quickest European company ever to achieve a unicorn valuation.

Retinal disease drug developer Gyroscope Therapeutics has raised series C funding from investors including Fosun Pharma.